October 2024 in “Journal of the Endocrine Society” Estrogen alone can lower testosterone in some transfeminine people.
October 2024 in “Journal of the Endocrine Society” Estrogen alone may effectively suppress testosterone in some transfeminine individuals.
February 2024 in “Hormones” Future hormone therapy trials should match the diverse needs and priorities of the gender-diverse community.
120 citations,
October 2007 in “Clinical Interventions in Aging” Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.
28 citations,
August 2000 in “Current Opinion in Chemical Biology” Future osteoporosis treatments should focus on increasing bone growth, with many promising options available.
15 citations,
September 2021 in “Frontiers in Endocrinology” Hormone therapy increases the risk of heart-related issues in transgender women and may affect heart health in transgender men.
36 citations,
May 2017 in “The journal of sexual medicine” Cyproterone acetate treatment is safe and causes mild feminization, which increases with added estrogen.
1 citations,
November 2007 in “Neuro-chirurgie/Neurochirurgie” Cyproterone acetate is a safe treatment that causes modest feminization in transgender female adolescents, and works better with added estrogens.
8 citations,
January 1996 in “Gynecological Endocrinology” Cyproterone acetate is the preferred treatment for women's hyperandrogenism when estrogen/progestogen use is safe.
March 2023 in “JAAD case reports” 166 citations,
October 2018 in “Endocrine Reviews” Hormone treatments for transgender individuals generally improve mental health and physical transition, with some health risks that require medical supervision.
47 citations,
November 2012 in “Expert Opinion on Therapeutic Patents” The document concludes that research on sulfatase inhibitors should continue due to their potential in treating various diseases, despite some clinical trial failures.
37 citations,
February 2007 in “Clinical Obstetrics and Gynecology” The document concludes that treating PCOS requires a combination of drugs to manage reproductive and metabolic symptoms, with more research needed on combination therapies.
34 citations,
December 2015 in “Neuroscience & Biobehavioral Reviews” Some hormone-related drugs may protect brain cells in Parkinson's disease differently in men and women.
22 citations,
January 2017 in “Dermatology” Spironolactone is effective and safe for treating acne with minimal side effects.
21 citations,
April 2019 in “Endocrinology and Metabolism Clinics of North America” Transgender patients need proper skin care, especially when undergoing hormone treatments, to manage issues like acne and hair loss.
7 citations,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
February 2024 in “Biomedicines” Hormones like androgens, estrogen, thyroid hormones, and stress hormones can contribute to hair loss, and treatments target these hormonal imbalances.
November 2010 in “Clin-Alert” Monitoring for adverse effects in clinical treatments is crucial.
January 2024 in “Pharmaceutical medicine” Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
431 citations,
October 2008 in “Current Medicinal Chemistry” Coumarin derivatives show promise as anti-estrogenic agents for treating breast cancer, with some in clinical trials.
46 citations,
February 2012 in “Oncology Reports” Sorafenib helps some advanced cancers alone or with other treatments, but not all, and research continues to improve its use.
25 citations,
July 2013 in “Actas Dermo-Sifiliográficas” Acitretin is effective for severe psoriasis and can be used long-term due to no immunosuppression, but must be carefully monitored for side effects and is not for pregnant women.
22 citations,
November 2018 in “Breast Cancer Research and Treatment” The medications 5α-reductase inhibitors and spironolactone are generally safe for breast cancer patients on endocrine therapies and do not significantly increase breast cancer risk.
1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
82 citations,
May 2016 in “Best Practice & Research in Clinical Obstetrics & Gynaecology” The conclusion is that managing androgen excess requires long-term treatment, including hormonal contraceptives and androgen blockers, with follow-up after six months.
75 citations,
July 2013 in “The Journal of Clinical Endocrinology and Metabolism” Taking low-dose spironolactone and metformin together works better for PCOS symptoms than either drug alone.
66 citations,
September 2008 in “Dermatologic therapy” The conclusion is that the best initial treatment for hirsutism is usually oral contraceptives, with the addition of antiandrogens or insulin sensitizers if needed, and topical eflornithine or laser treatments as supplementary options.
30 citations,
October 2014 in “Journal of The American Academy of Dermatology” A team approach is crucial for managing PCOS, with dermatologists playing a key role.
26 citations,
March 2014 in “Journal of cutaneous medicine and surgery” Topical vitamin D is useful for some skin conditions but not effective for others, and more research is needed.